HU219223B - Process for producing medicaments comprising magnesium-pyridoxale-5'-phosphate-glutaminate which are useful for prevention diseases originated from blood-vessel-alternations - Google Patents
Process for producing medicaments comprising magnesium-pyridoxale-5'-phosphate-glutaminate which are useful for prevention diseases originated from blood-vessel-alternations Download PDFInfo
- Publication number
- HU219223B HU219223B HU756/91A HU175691A HU219223B HU 219223 B HU219223 B HU 219223B HU 756/91 A HU756/91 A HU 756/91A HU 175691 A HU175691 A HU 175691A HU 219223 B HU219223 B HU 219223B
- Authority
- HU
- Hungary
- Prior art keywords
- ldl
- phosphate
- mmol
- cholesterol
- active ingredient
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 11
- 239000003814 drug Substances 0.000 title claims description 7
- 230000002265 prevention Effects 0.000 title claims description 6
- 230000008569 process Effects 0.000 title claims description 5
- 201000010099 disease Diseases 0.000 title claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 4
- 150000002978 peroxides Chemical class 0.000 claims abstract description 23
- 208000035150 Hypercholesterolemia Diseases 0.000 claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 239000004480 active ingredient Substances 0.000 claims description 8
- 206010020772 Hypertension Diseases 0.000 claims description 6
- HFAKVRNAKYBCSN-RJXKWAGSSA-L magnesium (2S)-2,5-diamino-5-oxopentanoate (4-formyl-5-hydroxy-6-methylpyridin-3-yl)methyl hydrogen phosphate Chemical compound [Mg++].N[C@@H](CCC(N)=O)C([O-])=O.Cc1ncc(COP(O)([O-])=O)c(C=O)c1O HFAKVRNAKYBCSN-RJXKWAGSSA-L 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 230000003966 vascular damage Effects 0.000 claims description 3
- 230000001631 hypertensive effect Effects 0.000 claims description 2
- 230000001565 angiopathic effect Effects 0.000 claims 1
- 150000002696 manganese Chemical class 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 11
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 231100000216 vascular lesion Toxicity 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 50
- 108010007622 LDL Lipoproteins Proteins 0.000 description 22
- 102000007330 LDL Lipoproteins Human genes 0.000 description 22
- 235000012000 cholesterol Nutrition 0.000 description 20
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 12
- 229960004488 linolenic acid Drugs 0.000 description 12
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 12
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 11
- 230000006378 damage Effects 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 208000029078 coronary artery disease Diseases 0.000 description 9
- 235000005911 diet Nutrition 0.000 description 9
- 230000037213 diet Effects 0.000 description 9
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 6
- 239000005977 Ethylene Substances 0.000 description 6
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- FRIBMENBGGCKPD-UHFFFAOYSA-N 3-(2,3-dimethoxyphenyl)prop-2-enal Chemical compound COC1=CC=CC(C=CC=O)=C1OC FRIBMENBGGCKPD-UHFFFAOYSA-N 0.000 description 5
- 208000008589 Obesity Diseases 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 230000003511 endothelial effect Effects 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 235000020824 obesity Nutrition 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 201000010383 sebaceous gland neoplasm Diseases 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 208000019553 vascular disease Diseases 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 3
- 208000024248 Vascular System injury Diseases 0.000 description 3
- 208000012339 Vascular injury Diseases 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 208000006575 hypertriglyceridemia Diseases 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 3
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 3
- 229960001327 pyridoxal phosphate Drugs 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- PAJPWUMXBYXFCZ-UHFFFAOYSA-N 1-aminocyclopropanecarboxylic acid Chemical compound OC(=O)C1(N)CC1 PAJPWUMXBYXFCZ-UHFFFAOYSA-N 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- -1 lipid peroxides Chemical class 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 206010014476 Elevated cholesterol Diseases 0.000 description 1
- 206010014486 Elevated triglycerides Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000015337 arteriosclerotic cardiovascular disease Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229940083759 high-ceiling diuretics aryloxyacetic acid derivative Drugs 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-M hydroperoxide group Chemical group [O-]O MHAJPDPJQMAIIY-UHFFFAOYSA-M 0.000 description 1
- 230000000260 hypercholesteremic effect Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- QZIQJVCYUQZDIR-UHFFFAOYSA-N mechlorethamine hydrochloride Chemical compound Cl.ClCCN(C)CCCl QZIQJVCYUQZDIR-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- WHOMFKWHIQZTHY-UHFFFAOYSA-N pyridoxine 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(CO)=C1O WHOMFKWHIQZTHY-UHFFFAOYSA-N 0.000 description 1
- 150000003227 pyridoxines Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000018964 sebaceous gland cancer Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4016963A DE4016963A1 (de) | 1990-05-25 | 1990-05-25 | Verwendung von magnesium-pyridoxal-5'-phosphat-glutaminat zur verhinderung von erkrankungen, die sich infolge von gefaessschaeden ergeben |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| HU911756D0 HU911756D0 (en) | 1991-12-30 |
| HUT58204A HUT58204A (en) | 1992-02-28 |
| HU219223B true HU219223B (en) | 2001-03-28 |
Family
ID=6407228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU756/91A HU219223B (en) | 1990-05-25 | 1991-05-24 | Process for producing medicaments comprising magnesium-pyridoxale-5'-phosphate-glutaminate which are useful for prevention diseases originated from blood-vessel-alternations |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US5372999A (forum.php) |
| EP (1) | EP0458287B1 (forum.php) |
| JP (1) | JPH07119174B2 (forum.php) |
| KR (1) | KR970005180B1 (forum.php) |
| CN (1) | CN1050750C (forum.php) |
| AT (1) | ATE142884T1 (forum.php) |
| AU (1) | AU651108B2 (forum.php) |
| CA (1) | CA2043228C (forum.php) |
| CZ (1) | CZ280683B6 (forum.php) |
| DE (2) | DE4016963A1 (forum.php) |
| DK (1) | DK0458287T3 (forum.php) |
| EG (1) | EG19730A (forum.php) |
| ES (1) | ES2091262T3 (forum.php) |
| GR (1) | GR3021077T3 (forum.php) |
| HR (1) | HRP931445B1 (forum.php) |
| HU (1) | HU219223B (forum.php) |
| IE (1) | IE76728B1 (forum.php) |
| IL (1) | IL98156A (forum.php) |
| IN (1) | IN173057B (forum.php) |
| LT (1) | LT3335B (forum.php) |
| LV (1) | LV10046B (forum.php) |
| MD (1) | MD306C2 (forum.php) |
| MX (1) | MX171883B (forum.php) |
| RU (1) | RU2041713C1 (forum.php) |
| SI (1) | SI9110925A (forum.php) |
| SK (1) | SK278896B6 (forum.php) |
| UA (1) | UA26973A1 (forum.php) |
| ZA (1) | ZA913692B (forum.php) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19527820A1 (de) * | 1995-07-28 | 1997-01-30 | Leniger Follert Elfriede Prof | Arzneimittel zur Behandlung von Ulcera, insbesondere bei arteriellen und venösen Durchblutungsstörungen der Extremitäten, bei chronisch venöser Insuffizienz und Lymphödem |
| DE19532625C2 (de) * | 1995-09-04 | 2000-04-20 | Steigerwald Arzneimittelwerk | Verfahren zur Herstellung von Magnesium-pyridoxal-5'-phosphat-glutamat und dabei erhaltene Zwischenprodukte |
| US6043259A (en) * | 1998-07-09 | 2000-03-28 | Medicure Inc. | Treatment of cardiovascular and related pathologies |
| DE60023125T2 (de) | 1999-03-08 | 2006-06-22 | University Of Manitoba, Winnipeg | Pyridoxal-analoge zur behandlung von störungen ausgelöst durch einen vitamin b6 mangel |
| WO2001003682A2 (en) * | 1999-07-13 | 2001-01-18 | Medicure Inc. | Use of pyridoxin derivatives for the treatment of diabetes and related complications |
| AU783855B2 (en) * | 1999-08-24 | 2005-12-15 | Medicure International Inc. | Compositions for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds |
| US7442689B2 (en) * | 2000-02-29 | 2008-10-28 | Medicure International Inc. | Cardioprotective phosphonates and malonates |
| AU3718501A (en) | 2000-02-29 | 2001-09-12 | Medicure Int Inc | Cardioprotective phosphonates and malonates |
| AU784840B2 (en) | 2000-03-28 | 2006-07-06 | Medicure International Inc. | Treatment of cerebrovascular disease |
| RU2163132C1 (ru) * | 2000-06-01 | 2001-02-20 | Научно-исследовательский центр традиционной фитотерапии | Способ лечения сердечно-сосудистых заболеваний фитопрепаратом и лекарственный сбор для лечения сердечно-сосудистых заболеваний |
| US6548519B1 (en) | 2001-07-06 | 2003-04-15 | Medicure International Inc. | Pyridoxine and pyridoxal analogues: novel uses |
| US6897228B2 (en) | 2000-07-07 | 2005-05-24 | Medicure International Inc. | Pyridoxine and pyridoxal analogues: new uses |
| NZ523815A (en) | 2000-07-07 | 2004-07-30 | Medicure Int Inc | Pyridoxine and pyridoxal analogues: cardiovascular therapeutics |
| US20070060549A1 (en) * | 2004-08-10 | 2007-03-15 | Friesen Albert D | Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders |
| WO2006050598A1 (en) | 2004-10-28 | 2006-05-18 | Medicure International Inc. | Dual antiplatelet/anticoagulant pyridoxine analogs |
| US7459468B2 (en) | 2004-10-28 | 2008-12-02 | Medicure International, Inc. | Aryl sulfonic pyridoxines as antiplatelet agents |
| EP2129780A2 (en) | 2007-03-14 | 2009-12-09 | Sierra Molecular Corporation | Compositions, systems, and methods for preservation and/or stabilization of a cell and/or macromolecule |
| RU2484843C1 (ru) * | 2012-04-03 | 2013-06-20 | Алексей Кириллович Пехтерев | Лекарственный сбор растений для лечения сердечно-сосудистых заболеваний |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE246172C (forum.php) | ||||
| DE2461742C2 (de) * | 1974-12-28 | 1983-01-27 | Steigerwald Arzneimittelwerk Gmbh, 6100 Darmstadt | Pyridoxin-5'-phosphorsäureester-Derivate sowie deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| DE3807895A1 (de) * | 1988-03-10 | 1989-09-21 | Knoll Ag | Erzeugnisse, enthaltend einen calciumantagonisten und einen lipidsenker |
-
1990
- 1990-05-25 DE DE4016963A patent/DE4016963A1/de active Granted
-
1991
- 1991-05-13 IN IN362CA1991 patent/IN173057B/en unknown
- 1991-05-15 ZA ZA913692A patent/ZA913692B/xx unknown
- 1991-05-16 IL IL9815691A patent/IL98156A/en active IP Right Grant
- 1991-05-22 EP EP91108217A patent/EP0458287B1/en not_active Expired - Lifetime
- 1991-05-22 ES ES91108217T patent/ES2091262T3/es not_active Expired - Lifetime
- 1991-05-22 AT AT91108217T patent/ATE142884T1/de not_active IP Right Cessation
- 1991-05-22 DK DK91108217.0T patent/DK0458287T3/da active
- 1991-05-22 DE DE69122170T patent/DE69122170T2/de not_active Expired - Fee Related
- 1991-05-22 KR KR1019910008233A patent/KR970005180B1/ko not_active Expired - Fee Related
- 1991-05-22 EG EG32091A patent/EG19730A/xx active
- 1991-05-23 SI SI9110925A patent/SI9110925A/sl unknown
- 1991-05-24 RU SU914895539A patent/RU2041713C1/ru active
- 1991-05-24 UA UA4895539A patent/UA26973A1/uk unknown
- 1991-05-24 MX MX025919A patent/MX171883B/es unknown
- 1991-05-24 HU HU756/91A patent/HU219223B/hu not_active IP Right Cessation
- 1991-05-24 JP JP3149739A patent/JPH07119174B2/ja not_active Expired - Lifetime
- 1991-05-24 AU AU77301/91A patent/AU651108B2/en not_active Ceased
- 1991-05-24 CZ CS911563A patent/CZ280683B6/cs not_active IP Right Cessation
- 1991-05-24 SK SK1563-91A patent/SK278896B6/sk unknown
- 1991-05-24 IE IE178391A patent/IE76728B1/en not_active IP Right Cessation
- 1991-05-24 CA CA002043228A patent/CA2043228C/en not_active Expired - Fee Related
- 1991-05-25 CN CN91104365A patent/CN1050750C/zh not_active Expired - Fee Related
-
1993
- 1993-04-02 US US08/041,896 patent/US5372999A/en not_active Expired - Fee Related
- 1993-05-14 LV LVP-93-343A patent/LV10046B/en unknown
- 1993-05-31 LT LTIP580A patent/LT3335B/lt not_active IP Right Cessation
- 1993-11-26 HR HRP-925/91A patent/HRP931445B1/xx not_active IP Right Cessation
-
1994
- 1994-11-25 MD MD94-0391A patent/MD306C2/ro active IP Right Grant
-
1996
- 1996-09-19 GR GR960402156T patent/GR3021077T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HU219223B (en) | Process for producing medicaments comprising magnesium-pyridoxale-5'-phosphate-glutaminate which are useful for prevention diseases originated from blood-vessel-alternations | |
| Taylor et al. | Octacosanol in human health | |
| Kannel et al. | An update on coronary risk factors | |
| Salonen et al. | The Kuopio Atherosclerosis Prevention Study (KAPS): Effect of pravastatin treatment on lipids, oxidation resistance of lipoprotems, and atherosclerotic progression | |
| Kapoor et al. | Coenzyme Q10-a novel molecule | |
| Leinonen et al. | Rye bread decreases serum total and LDL cholesterol in men with moderately elevated serum cholesterol | |
| EP1707572A2 (en) | Sterol compositions from pulping soap | |
| KR20010022385A (ko) | 암로디핀 및 스타틴 화합물을 포함하는 복합 조성물 | |
| Miwa et al. | Effects of glucosyl hesperidin on serum lipids in hyperlipidemic subjects: preferential reduction in elevated serum triglyceride level | |
| MXPA03010080A (es) | Uso de flavonas polimetoxiladas para tratar la resistencia a la insulina. | |
| Poulter et al. | Lipid profiles after the daily consumption of an oat-based cereal: a controlled crossover trial | |
| Kooyenga et al. | Palm oil antioxidant effects in patients with hyperlipidaemia and carotid stenosis-2 year experience. | |
| Quérin et al. | Single‐dose pharmacokinetics of 14C‐lovastatin in chronic renal failure | |
| Brattström et al. | Pyridoxine reduces cholesterol and low-density lipoprotein and increases antithrombin III activity in 80-year-old men with low plasma pyridoxal 5-phosphate | |
| Rajasekaran et al. | Hypolipidemic and antioxidant activity of aqueous extract of Monascus purpureus fermented Indian rice in high cholesterol diet fed rats | |
| US20060009486A1 (en) | Composition and method for treatment and prevention of coronary artery disease | |
| Hasibeder et al. | Clinical pharmacology of the hypocholesterolemic agent K 12.148 (lifibrol) in healthy volunteers | |
| Chin-Dusting et al. | Lipids and atherosclerosis: clinical management of hypercholesterolaemia | |
| EP1414523A2 (de) | Verwendung eines lactatsalzes zur behandlung und prophylaxe der atherosklerose | |
| Grundy | Clinical Applications and Therapeutic Potential | |
| JPS60190717A (ja) | 脂質低下剤 | |
| JPH1087480A (ja) | 抗動脈硬化治療剤 | |
| Basit et al. | Frequency of statin use in type 2 diabetics having macrovascular disease-at a Tertiary Care Hospital of Karachi | |
| Trial et al. | Cardiovascular Benefits of Omega-3 Polyunsaturated Fatty Acids 81 B. Maisch and R. Oelze (Eds.) IOS Press, 2006© 2006 The authors. All rights reserved. | |
| Colhoun et al. | Cholesterol lowering with atorvastatin for the primary prevention of cardiovascular disease in diabetic adults |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HMM4 | Cancellation of final prot. due to non-payment of fee |